1. Introduction {#sec1}
===============

Areca nut is the seed of the palm tree *Areca catechu*, which is the fourth most commonly used psychoactive substance, after caffeine, nicotine, and alcohol \[[@B1]\]. Because areca nut is always consumed with the leaf of *Piper betle*, chewing of areca nut has always been referred to as "betel nut chewing" in the English literature \[[@B2]\]. There is an estimated 600 million people chewing betel nut worldwide \[[@B3]\].It is a common habit and is a means of social interaction in Asia, particularly the South Pacific islands, Southeast Asia, Papua New Guinea, Bangladesh, Pakistan, and India \[[@B1]--[@B4]\]. Chewing of betel nut was forbidden in Taiwan during the Japanese reign more than 60 years ago \[[@B4]\]. But this habit has become popular in Taiwan during the past two to three decades, and it has been estimated that about 2.4 millions, or 11.4%, of the total population are chewing betel nut \[[@B5]\]. The chewing population in Taiwan keeps on increasing, especially in the male sex of the younger generation \[[@B6], [@B7]\]. In Taiwan, unripe areca nut is commonly chewed with a mixture of lime and the leaf or flower of the *Piper betle*, but without tobacco \[[@B4]\].

Betel nut chewing has been linked to a variety of health problems including oral lesions of leukoplakia, submucosal fibrosis, squamous cell carcinoma and periodontal disease \[[@B8], [@B9]\], albuminuria in diabetic patients \[[@B10]\], disruption of gastric mucosal barriers \[[@B11]\], aggravation of asthma \[[@B12]\], induction of extrapyramidal syndrome \[[@B13]\], milk-alkali syndrome (in a case report) \[[@B14]\], induction of uterine cervical dysplasia \[[@B15]\], cancers of the esophagus \[[@B16]\] and liver \[[@B17]\], and low birth weight of babies born to mothers chewing betel nut \[[@B18]\]. In more recent population-based studies in Taiwan, betel nut chewing is also associated with a higher risk of type 2 diabetes mellitus (T2DM) \[[@B19]\], hypertension \[[@B20]\], and total and cerebrovascular deaths \[[@B21]\].

Studies on the cardiovascular effects of betel nut chewing are rare. Hemodynamic changes have been observed during betel nut chewing \[[@B7]\]. However, whether the prolonged chewing of betel nut could exert an effect on the heart has not been previously studied. Therefore, the purpose of this study was to evaluate whether betel nut chewing could be associated with the prevalence of subclinical IHD in a subgroup of patients with T2DM recruited as a long-term follow-up cohort in Taiwan.

2. Methods {#sec2}
==========

2.1. Study Subjects {#sec2.1}
-------------------

The study was approved by an ethics committee of the Department of Health, Taiwan, and the subjects voluntarily participated in the study. More than 96% of the population of Taiwan is covered by a compulsory National Health Insurance program. A total of 256,036 patients using this health insurance program were assembled from 1995 to 1998 \[[@B22]--[@B24]\]. Baseline data was collected by questionnaires on the onset symptoms and confirmation of diabetic diagnosis from 93,484 patients of the original cohort \[[@B22]--[@B24]\]. At random, 4,164 patients were selected from the main cluster of 93,484 patients and invited to participate in a health examination. A total of 1,441 patients participated in the health examination from March 1998 to September 2002. After excluding 21 patients with type 1 diabetes mellitus (T1DM), there were a total of 1420 patients diagnosed as T2DM. The patients with T2DM did not show a history of diabetic ketoacidosis at the onset of diabetes and were being treated with either oral antidiabetic drugs or insulin at the time of recruitment. For those under insulin treatment, none received such treatment within one year of diagnosis of diabetes mellitus.

Patients with T1DM were excluded because of the small number of cases who might also have different pathogenesis of IHD. Women with T2DM were further excluded because the habit of betel nut chewing is very uncommon in women in Taiwan \[[@B6], [@B7], [@B25]\]. Taking into account the possible requirement of prolonged chewing for the manifestations of clinical outcomes, this study recruited only adult male patients aging ≥45 years, and chewers must be current chewers and have retained the habit for ≥5 years at the time of recruitment. Patients with a clinical history of heart disease including angina pectoris, myocardial infarction, congestive heart failure or under treatment for such were also excluded because of the impossibility to clarify the correctness of temporality between cause and effects and because of the potential confounding effect caused by treatments. As a result, a total of 394 men with T2DM were included in this study. They were divided into two groups: one with no habit of chewing betel nut and the other should have persistently chewed betel nut for more than 5 years at the time of recruitment.

2.2. Diagnosis of Subclinical Ischemic Heart Disease {#sec2.2}
----------------------------------------------------

Resting electrocardiogram was performed in each subject, and the Minnesota codes were used to code the electrocardiograms. The coder was blind to the history or the biochemical data of the subjects. Subclinical IHD was defined by Minnesota codes of coronary probable (1.1, 1.2, 7.1) and coronary possible (1.3, 4.1--4.3, 5.1--5.3) \[[@B26]\].

2.3. Measurements of Blood Biochemistry and Other Covariates {#sec2.3}
------------------------------------------------------------

Blood samples were collected in the early morning after fasting for at least 12 hours. Fasting plasma glucose (FPG), serum total cholesterol (TC), and triglyceride (TG) were measured by an automatic biochemistry analyzer (Cobas Mira S, Roche Diagnostica, Basel, Switzerland) with reagents obtained from Randox Laboratories Ltd. (Antrium, UK) \[[@B27]\].

The patients\' age, duration of diabetes, body mass index (BMI), smoking status, and systolic (SBP) and diastolic blood pressure (DBP) were recorded or measured. Duration of diabetes was defined as the time period in years between the time being recruited into the study and the time diabetes was diagnosed. Blood pressure was measured on the right arm after 20 minutes rest in a sitting position with a mercury sphygmomanometer by the auscultatory method. Body height (in centimeters) was measured by having the subjects stand with their heals, buttocks, and heads against a wall. A flat object was placed on top of the subjects\' head, and their height was marked on a tape measure affixed to the wall. Body weight was measured in kilograms with a standard portable scale. Body height and body weight were measured with the patient wearing light clothes and without socks and shoes. BMI was calculated as body weight in kilograms divided by the square of the body height in meters. Hypertension was defined by a positive history with the use of antihypertensive agents or by SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg. Dyslipidemia was diagnosed by the use of lipid-lowering agents and/or a TC level ≥ 200 mg/dL and/or TG ≥ 150 mg/dL.

2.4. Statistical Analyses {#sec2.4}
-------------------------

Data were expressed as mean (SD) or percentage. A *P* \< .05 was considered statistically significant, while .05 \< *P* \< .1 was borderline significant. Age was divided into two groups by the median and the prevalences of subclinical IHD between chewers and nonchewers were compared by Chi-square test in the respective age groups. The baseline characteristics between chewers and nonchewers and between patients with subclinical IHD and those without subclinical IHD were compared by Student\'s *t*-test for continuous variables and by Chi-square test for categorical variables. Logistic regression models estimating the odds ratios for subclinical IHD were created for all patients and for patients in the respective two age groups divided by the median of age. These regression models were generated in the following 3 ways: (1) unadjusted; (2) adjusted for variables found to be different between chewers and non-chewers, or between patients with and without subclinical IHD with *P* values \<  .1; (3) adjusted for all potential covariates (i.e., age, diabetic duration, body mass index, smoking, hypertension, dyslipidemia, FPG, SBP, DBP, TC, and TG).

3. Results {#sec3}
==========

[Figure 1](#fig1){ref-type="fig"} shows the prevalences of subclinical IHD in chewers and non-chewers in the respective age groups divided by the median of 63 years old.The prevalences of subclinical IHD differed significantly between chewers and non-chewers in either the younger or the older age groups (*P* \< .05).

[Table 1](#tab1){ref-type="table"} compares the baseline characteristics between chewers and nonchewers and between patients with and without subclinical IHD. Chewers were significantly younger in age, more prevalent in smoking and subclinical IHD, and had higher BMI and poorer glycemic control. Patients with subclinical IHD were significantly older and more prevalent in betel nut chewing.

[Table 2](#tab2){ref-type="table"} shows the odds ratios for subclinical IHD. Chewers consistently showed a significantly higher risk of subclinical IHD in either the older or the younger age group in all of the models.

4. Discussion {#sec4}
=============

The findings of this study clearly demonstrated a higher risk of subclinical IHD in T2DM patients without a previous history of heart disease (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}; [Figure 1](#fig1){ref-type="fig"}). This association was independent of traditional risk factors, and could be demonstrated in either the younger or the older patients ([Figure 1](#fig1){ref-type="fig"}; [Table 2](#tab2){ref-type="table"}). To the best of our knowledge, this was the first study demonstrating a link between betel nut chewing and subclinical IHD. The association was consistent, and the magnitude of the odds ratios was large.

Although the real pathogenetic mechanism(s) remains unknown, some of the biological effects associated with the ingredients of areca nut or the compounds formed during chewing might explain some of the possibilities. The common preparations of the betel nut quid in Taiwan consist of three major components: the nut of *Areca catechu*, quicklime, and the leaf or the flower of *Piper betle* \[[@B4]\]. Areca nut contains arecoline which has a cholinergic action at the muscarinic and nicotinic receptors \[[@B28]\]. This cholinergic action on the central nervous system could possibly produce the cortical arousal and alertness which is always claimed as one of the merits experienced by the betel nut chewers. On the other hand, arecoline might stimulate the hypothalamic-pituitary-adrenal axis through a centrally mediated corticotrophin-releasing hormone-dependent mechanism in rats \[[@B29]\]. In the presence of lime, arecoline is hydrolyzed to arecaidine, which lacks the parasympathomimetic effects of arecoline \[[@B4]\] and exerts sympathetic effect by inhibition of *γ*-aminobutyric acid (GABA) uptake \[[@B30]\]. However, a later study suggested that arecaidine may not cross the blood-brain barrier and the central effects may involve transmitters other than GABA \[[@B31]\]. The aromatic substances (e.g., eugenol, isoeugenol, and hydroxychavicol) in the flower or leaf of*Piper betle* can stimulate the release of catecholamines from chromaffin cells *in vitro* \[[@B32]\], and circulating norepinephrine and epinephrine levels are elevated following betel nut chewing \[[@B33]\]. However, these sympathomimetic effects of arecoline might be mediated by central cholinergic mechanisms \[[@B34]\]. Therefore, both areca nut and *Piper betle*flower may exert sympathomimetic effects. Whether these sympathomimetic effects may be responsible for the subclinical IHD observed in the present study awaits further investigations. Reactive oxygen species and *N*-nitroso compounds can also be formed in the oral cavity during chewing of betel nut \[[@B35], [@B36]\]. *In vitro*studies also demonstrated that betel nut components increased the release of inflammatory mediators such as prostanoids, interleukin-6, and tumor necrosis factor-*α* \[[@B37], [@B38]\]. The production of these chemical agents has always been regarded as the mediators of carcinogenicity and diabetogenicity associated with betel nut chewing. Whether they can also be responsible for a hemodynamic or structural change in the coronary vascular system leading to subclinical IHD is an issue worthy of further investigation.

Some limitations deserve mentioning. This study was conducted in the diabetic patients, and it is not known whether similar effects can be extended to the general population without diabetes. Future studies should be aimed at a dose-response relationship and taking the duration of betel nut chewing into consideration. Longitudinal prospective studies are required to clarify the cause/effect relationship between betel nut chewing and subclinical IHD.

In conclusions, betel nut chewing in Taiwanese patients with T2DM is associated with subclinical IHD. While the chewing of betel nut is decreasing in some countries like Thailand \[[@B39]\], the prevalence keeps on increasing in Taiwan, especially in the younger generation. It is urgent for policy makers to implement programs of health education to the younger generation to curb the increasing prevalence of betel nut chewing and its associated health problems.
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###### 

Comparisons between patients chewing and not chewing betel nut and having and not having subclinical ischemic heart disease (IHD).

                                   Betel nut chewing   Subclinical IHD                   
  -------------------------------- ------------------- ----------------- --------------- ----------------
  *n*                              349                 45                323             71
  Age, years                       63.9 (9.3)          56.3 (8.6)\*\*    62.0 (9.4)      67.6 (9.1)\*\*
  Diabetic duration, years         10.4 (7.6)          10.3 (8.8)        10.4 (7.6)      10.7 (8.5)
  Body mass index, kg/m^2^         24.5 (3.0)          25.9 (3.7)\*\*    24.6 (3.2)      24.8 (2.9)
  Smoking, %                       60.5                86.7\*\*          63.2            64.8
  Fasting plasma glucose, mg/dL    159.4 (57.3)        178.6 (74.8)\*    162.2 (56.5)    159.1 (72.9)
  Hypertension, %                  52.4                60.0              52.3            57.8
  Systolic blood pressure, mmHg    132.8 (15.8)        131.9 (16.1)      132.1 (15.4)    135.2 (17.5)
  Diastolic blood pressure, mmHg   83.2 (8.8)          84.8 (7.0)        83.4 (8.4)      83.1 (9.6)
  Dyslipidemia, %                  56.0                68.9              56.5            62.0
  Total cholesterol, mg/dL         199.8 (45.9)        196.9 (38.2)      199.1 (45.1)    201.3 (44.9)
  Triglyceride, mg/dL              168.7 (193.3)       180.0 (83.1)      168.9 (196.2)   174.9 (114.6)
  Ischemic heart disease, %        16.6                28.9\*            ---             ---
  Betel nut chewing, %             ---                 ---               9.9             18.0\*

\**P* \< .05; \*\**P* \< .01.

###### 

Odds ratios for subclinical ischemic heart disease comparing chewers versus nonchewers of betel nut.

                                                                                                                              Odds ratio (95% confidence interval)                             
  --------------------------------------------------------------------------------------------------------------------------- -------------------------------------- ------------------------- ---------------------------
  Unadjusted                                                                                                                  2.982 (1.087--8.182)\*                 3.267 (1.004--10.629)\*   2.038 (1.008--4.118)\*
  Adjusted for age, BMI, smoking, and FPG                                                                                     4.153 (1.280--13.471)\*                4.183 (1.170--14.955)\*   4.269 (1.837--9.920)\*\*
  Adjusted for all covariates (age, diabetic duration, BMI, smoking, hypertension, dyslipidemia, FPG, SBP, DBP, TC, and TG)   4.724 (1.346--16.581)\*                4.666 (1.278--17.028)\*   4.640 (1.958--10.999)\*\*

\**P* \< .05; \*\**P* \< .01.
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